ChemoCentryx Inc. (NASDAQ:CCXI) dropped 3.4% on Tuesday . The company traded as low as $4.16 and last traded at $4.22, with a volume of 113,417 shares traded. The stock had previously closed at $4.37.

CCXI has been the topic of a number of research reports. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Wednesday, April 27th. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a report on Thursday, May 19th. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $11.00 price target on shares of ChemoCentryx in a report on Tuesday.

The company’s 50 day moving average price is $4.60 and its 200 day moving average price is $3.77. The company’s market cap is $187.79 million.

ChemoCentryx (NASDAQ:CCXI) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by $0.07. On average, equities analysts forecast that ChemoCentryx Inc. will post ($0.35) earnings per share for the current year.

In other ChemoCentryx news, Director Geoffrey M. Parker bought 40,000 shares of the business’s stock in a transaction on Friday, May 13th. The shares were purchased at an average price of $4.03 per share, with a total value of $161,200.00. Following the completion of the acquisition, the director now directly owns 13,514 shares of the company’s stock, valued at approximately $54,461.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas A. Edwards bought 50,000 shares of the business’s stock in a transaction on Tuesday, May 17th. The stock was acquired at an average cost of $4.05 per share, for a total transaction of $202,500.00. Following the acquisition, the director now directly owns 91,977 shares of the company’s stock, valued at $372,506.85. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in ChemoCentryx stock. Westfield Capital Management Co. LP raised its position in shares of ChemoCentryx Inc. (NASDAQ:CCXI) by 1.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,102,332 shares of the biopharmaceutical company’s stock after buying an additional 19,375 shares during the period. Westfield Capital Management Co. LP owned about 2.50% of ChemoCentryx worth $8,929,000 at the end of the most recent reporting period.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.